Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.02, FiscalAI reports. The firm had revenue of $0.02 million for the quarter.
Neumora Therapeutics Stock Down 13.8%
Shares of NASDAQ:NMRA opened at $0.37 on Tuesday. The company has a market capitalization of $69.43 million, a price-to-earnings ratio of -0.30 and a beta of 3.12. Neumora Therapeutics has a 12-month low of $0.32 and a 12-month high of $3.65. The business has a 50-day moving average price of $0.58 and a 200 day moving average price of $1.69. The company has a current ratio of 4.50, a quick ratio of 4.50 and a debt-to-equity ratio of 1.19.
Insider Buying and Selling
In other Neumora Therapeutics news, insider Daljit Singh Aurora sold 67,741 shares of the stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $1.51, for a total transaction of $102,288.91. Following the completion of the transaction, the insider owned 48,750 shares of the company’s stock, valued at $73,612.50. This trade represents a 58.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 237,978 shares of company stock valued at $371,554 over the last 90 days. Corporate insiders own 26.94% of the company’s stock.
Analysts Set New Price Targets
Several analysts have recently weighed in on NMRA shares. Wall Street Zen raised shares of Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 7th. HC Wainwright reaffirmed a “buy” rating on shares of Neumora Therapeutics in a research report on Tuesday, July 28th. Finally, Weiss Ratings upgraded Neumora Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.17.
Read Our Latest Research Report on NMRA
About Neumora Therapeutics
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. Founded in 2020 and headquartered in Watertown, Massachusetts, the company researches potential medicines for conditions including depression, schizophrenia and agitation associated with Alzheimer’s disease. The company combines neuroscience research with data science and other computational approaches to identify disease targets and develop drug candidates. Its pipeline includes investigational medicines designed to act on specific biological pathways involved in brain disorders; these products are under development and are not approved treatments.
Read More
- Five stocks we like better than Neumora Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
